ARST1321 Non-Rhabdomyosarcoma Soft Tissue Sarcoma Study (PRO00002426)

If you choose to participate, you will be randomly assigned to one of 4 regimens.  If you are assigned to Regimen A (the experimental regimen), you will take pazopanib hydrochloride once a day (QD) by mouth (PO) on weeks 1-12, ifosfamide IV over 204 hours on days 1-3 on weeks 1, 4, 7, 10, and doxorubicin hydrochloride IV over 1-15 minutes on days 1-2 on weeks 1 and 4.  You will undergo radiation therapy on y weeks 4-10.  On week 13, you will undergo surgery.  You will then take pazopanib hydrochloride once a day by mouth on weeks 16-25, ifosfamide IV over 2-4 hours on days 1-3 on weeks 16 and 19, and doxorubicin hydrochloride IV over 1-15 minutes on days 1-2 on weeks 16, 19, and 22.  You will then undergo radiation therapy on weeks 16-25. 

If you are assigned to Regimen B, you will receive ifosfamide IV over 2-4 hours on days 1-3 on weeks 1, 4, 7, 10 and doxorubicin hydrochloride IV over 1-15 minutes on days 1-2 on weeks 1 and 4.  You will then undergo radiation therapy on weeks 4-10.  You will then undergo surgery on week 13.  You will then receive ifosfamide IV over 2-4 hours on days 1-3 on weeks 16 and 19 and doxorubicin hydrochloride IV over 1-15 minutes on days 1-2 on weeks 16, 19, and 22.  Patients undergo radiation therapy on weeks 16-25. 

If you are assigned to Regimen C (also an experimental arm), you will take pazopanib hydrochloride once a day by mouth on weeks 1-9.  You with then undergo radiation therapy on weeks 1-7.  On week 10, you will undergo surgery.  You will then take pazopanib hydrochloride once a day by mouth on weeks 13-25.  You will then undergo radiation therapy on weeks 13-16. 

If you are assigned to Regimen D, you will undergo radiation therapy on weeks 1-7.  You will then undergo surgery on week 10.  You will then undergo radiation therapy on weeks 13-16.